HLA-B27 status predicts radiographic phenotype of axSpAMarch 2, 2020Ankylosing spondylitisSpondyloarthropathiesPsoriatic Arthritis
Meta-analysis highlights safety concerns with interleukin inhibitionMarch 2, 2020Rheumatoid ArthritisMixed TopicsPediatricsAnkylosing spondylitisPsoriatic ArthritisSpondyloarthropathies
New guideline offers recommendations for reproductive health in patients with rheumatic diseasesMarch 2, 2020Lupus & Connective Tissue DiseasesAnkylosing spondylitisRheumatoid ArthritisPsoriatic ArthritisSpondyloarthropathies
Anti–TNF-alpha nonresponse in axSpA predicted by socioeconomic, patient-reported factorsFebruary 19, 2020Ankylosing spondylitisSpondyloarthropathies
In rheumatology, biosimilars are flatlining. Why?January 27, 2020Rheumatoid ArthritisSpondyloarthropathiesPsoriatic ArthritisPediatricsAnkylosing spondylitis
TNFi treatment shows hint of slowing axial spondyloarthritis radiographic progressionJanuary 22, 2020Ankylosing spondylitisSpondyloarthropathies
Repeat LTBI testing best in patients taking biologics with new risk factorsDecember 9, 2019Rheumatoid ArthritisPsoriatic ArthritisSpondyloarthropathiesAnkylosing spondylitisLupus & Connective Tissue Diseases
FDA approves infliximab-axxq for numerous indicationsDecember 6, 2019Rheumatoid ArthritisSpondyloarthropathiesAnkylosing spondylitisPsoriatic Arthritis
Evidence grows for early axSpA treatment, uveitis flare preventionDecember 6, 2019Ankylosing spondylitisSpondyloarthropathies
Certolizumab may reduce uveitis flares, axSpA disease activityDecember 6, 2019Ankylosing spondylitisSpondyloarthropathies
Upadacitinib doubles ASAS 40 response vs. placebo in ankylosing spondylitisDecember 3, 2019Ankylosing spondylitisSpondyloarthropathies
Certolizumab safety profile varies widely across indicationsNovember 27, 2019Psoriatic ArthritisRheumatoid ArthritisSpondyloarthropathies
More studies like VERVE needed to test live vaccines in special populationsNovember 25, 2019Rheumatoid ArthritisAnkylosing spondylitisSpondyloarthropathiesPsoriatic Arthritis
Newer IL-17 inhibitors make their case in phase 3 nonradiographic axial spondyloarthritis trialsNovember 21, 2019Ankylosing spondylitisSpondyloarthropathies
COAST-X top-line results: Ixekizumab improves nonradiographic axSpA vs. placeboNovember 21, 2019Ankylosing spondylitisSpondyloarthropathies
